Carsten Thiel Insider Trading $ALXN ALEXION PHARMACEUTICALS, INC.
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Carsten Thiel.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Carsten Thiel. Carsten Thiel is Chief Executive Officer in ABEONA THERAPEUTICS INC. ($AKC) and EVP, Chief Commercial Officer in ALEXION PHARMACEUTICALS INC ($ALXN) and SVP, EMEA & Asia Pacific in ALEXION PHARMACEUTICALS INC ($ALXN) and Director in Karyopharm Therapeutics Inc. ($KPTI).
Carsten Thiel in ALEXION PHARMACEUTICALS, INC.
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Position of Carsten Thiel: EVP, Chief Commercial Officer, SVP, EMEA & Asia Pacific
Holdings: 33,860 shares
Current Value: $4,324,599
Latest Transaction: Mar 06 2017
$ALXN Market Capitalization: $28.30B
$ALXN Previous Close: $127.72
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD
Latest Insider Trading Transactions of Carsten Thiel in ALEXION PHARMACEUTICALS, INC.
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, AKC, ALXN, KPTI
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 06 2017 | ALXN | ALEXION PHARMACEUT ... | Thiel Carsten | EVP, Chief Commerci ... | Sell | S | 131.01 | 3,783 | 495,611 | 33,860 | 37.6 K to 33.9 K (-10.05 %) |
| Mar 01 2017 | ALXN | ALEXION PHARMACEUT ... | Thiel Carsten | EVP, Chief Commerci ... | Option Exercise | A | 131.25 | 14,800 | 1,942,500 | 29,600 | |
| Mar 01 2017 | ALXN | ALEXION PHARMACEUT ... | Thiel Carsten | EVP, Chief Commerci ... | Grant | A | 0.00 | 7,500 | 0 | 37,643 | 30.1 K to 37.6 K (+24.88 %) |
| Mar 01 2017 | ALXN | ALEXION PHARMACEUT ... | Thiel Carsten | EVP, Chief Commerci ... | Sell | S | 0.00 | 54 | 0 | 30,143 | 30.2 K to 30.1 K (-0.18 %) |
| Mar 01 2017 | ALXN | ALEXION PHARMACEUT ... | Thiel Carsten | EVP, Chief Commerci ... | Sell | S | 131.20 | 71 | 9,315 | 30,197 | 30.3 K to 30.2 K (-0.23 %) |
| Feb 08 2017 | ALXN | ALEXION PHARMACEUT ... | Thiel Carsten | EVP, Chief Commerci ... | Sell | S | 125.69 | 165 | 20,739 | 30,268 | 30.4 K to 30.3 K (-0.54 %) |
| Dec 13 2016 | ALXN | ALEXION PHARMACEUT ... | Thiel Carsten | EVP, Chief Commerci ... | Sell | S | 130.00 | 2,308 | 300,040 | 30,433 | 32.7 K to 30.4 K (-7.05 %) |
| Oct 18 2016 | ALXN | ALEXION PHARMACEUT ... | Thiel Carsten | EVP, Chief Commerci ... | Sell | S | 120.28 | 4,584 | 551,364 | 32,741 | 37.3 K to 32.7 K (-12.28 %) |
| Oct 05 2016 | ALXN | ALEXION PHARMACEUT ... | Thiel Carsten | EVP, Chief Commerci ... | Sell | S | 122.41 | 29 | 3,550 | 37,325 | 37.4 K to 37.3 K (-0.08 %) |
| Sep 14 2016 | ALXN | ALEXION PHARMACEUT ... | Thiel Carsten | EVP, Chief Commerci ... | Sell | S | 129.00 | 3,000 | 387,000 | 37,354 | 40.4 K to 37.4 K (-7.43 %) |
| Sep 14 2016 | ALXN | ALEXION PHARMACEUT ... | Thiel Carsten | EVP, Chief Commerci ... | Sell | S | 124.20 | 225 | 27,945 | 40,354 | 40.6 K to 40.4 K (-0.55 %) |
| Sep 08 2016 | ALXN | ALEXION PHARMACEUT ... | Thiel Carsten | EVP, Chief Commerci ... | Sell | S | 125.94 | 1,000 | 125,940 | 40,579 | 41.6 K to 40.6 K (-2.41 %) |
| Mar 01 2016 | ALXN | ALEXION PHARMACEUT ... | Thiel Carsten | EVP, Chief Commerci ... | Option Exercise | A | 140.16 | 31,000 | 4,344,960 | 31,000 | |
| Mar 01 2016 | ALXN | ALEXION PHARMACEUT ... | Thiel Carsten | EVP, Chief Commerci ... | Sell | S | 138.91 | 54 | 7,501 | 41,579 | 41.6 K to 41.6 K (-0.13 %) |
| Mar 01 2016 | ALXN | ALEXION PHARMACEUT ... | Thiel Carsten | EVP, Chief Commerci ... | Grant | A | 0.00 | 5,000 | 0 | 41,633 | 36.6 K to 41.6 K (+13.65 %) |
| Feb 18 2016 | ALXN | ALEXION PHARMACEUT ... | Thiel Carsten | EVP, Chief Commerci ... | Sell | S | 143.49 | 187 | 26,833 | 36,633 | 36.8 K to 36.6 K (-0.51 %) |
| Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | Thiel Carsten | EVP, Chief Commerci ... | Grant | A | 0.00 | 8,802 | 0 | 36,820 | 28 K to 36.8 K (+31.42 %) |
| Nov 12 2015 | ALXN | ALEXION PHARMACEUT ... | Thiel Carsten | EVP, Chief Commerci ... | Sell | S | 173.34 | 3,000 | 520,020 | 28,018 | 31 K to 28 K (-9.67 %) |
| Oct 05 2015 | ALXN | ALEXION PHARMACEUT ... | Thiel Carsten | EVP, Chief Commerci ... | Option Exercise | A | 157.82 | 6,700 | 1,057,394 | 6,700 | |
| Oct 05 2015 | ALXN | ALEXION PHARMACEUT ... | Thiel Carsten | EVP, Chief Commerci ... | Grant | A | 0.00 | 2,000 | 0 | 31,018 | 29 K to 31 K (+6.89 %) |
| Sep 10 2015 | ALXN | ALEXION PHARMACEUT ... | Thiel Carsten | SVP, EMEA & Asia Pa ... | Sell | S | 170.88 | 12 | 2,051 | 29,018 | 29 K to 29 K (-0.04 %) |
| Sep 10 2015 | ALXN | ALEXION PHARMACEUT ... | Thiel Carsten | SVP, EMEA & Asia Pa ... | Sell | S | 169.15 | 800 | 135,320 | 29,030 | 29.8 K to 29 K (-2.68 %) |
| Mar 03 2015 | ALXN | ALEXION PHARMACEUT ... | Thiel Carsten | SVP, EMEA & Asia Pa ... | Option Exercise | A | 180.37 | 18,300 | 3,300,771 | 18,300 | |
| Mar 03 2015 | ALXN | ALEXION PHARMACEUT ... | Thiel Carsten | SVP, EMEA & Asia Pa ... | Grant | A | 0.00 | 3,830 | 0 | 29,830 | 26 K to 29.8 K (+14.73 %) |
Page: 1